| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
189,490,000 |
| Market
Cap: |
1.29(B) |
| Last
Volume: |
3,897,491 |
Avg
Vol: |
4,453,128 |
| 52
Week Range: |
$4.13 - $8.81 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 16.9 |
| Insider 6 Months : 16.9 |
| Insider 3/6 Months : 32.4 |
|
| Guru Rank Number : 455 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
183,601 |
183,601 |
183,601 |
183,601 |
| Total Buy Value |
$1,048,338 |
$1,048,338 |
$1,048,338 |
$1,048,338 |
| Total People Bought |
10 |
10 |
10 |
10 |
| Total Buy Transactions |
10 |
10 |
10 |
10 |
| Total Shares Sold |
0 |
0 |
16,866 |
495,199 |
| Total Sell Value |
$0 |
$0 |
$135,363 |
$5,999,241 |
| Total People Sold |
0 |
0 |
2 |
9 |
| Total Sell Transactions |
0 |
0 |
2 |
14 |
| End Date |
2024-03-05 |
2023-12-03 |
2023-06-04 |
2022-06-04 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Babu Yarlagadda S |
Chief Discovery Officer |
• • – |
2022-03-07 |
4 |
S |
$17.16 |
$343,200 |
D/D |
(20,000) |
230,056 |
|
33% |
|
| Jones Michael L |
Exec. Director, Finance - PAO |
• • – |
2022-03-01 |
4 |
S |
$17.20 |
$39,560 |
D/D |
(2,300) |
11,198 |
|
34% |
|
| Jones Michael L |
Exec. Director, Finance - PAO |
• • – |
2022-03-01 |
4 |
OE |
$4.73 |
$10,879 |
D/D |
2,300 |
13,498 |
|
- |
|
| Aselage Steve |
Director |
• • – |
2022-02-28 |
4 |
A |
$16.61 |
$5,000 |
D/D |
301 |
33,159 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2022-02-28 |
4 |
A |
$16.61 |
$9,999 |
D/D |
602 |
16,225 |
|
- |
|
| Ingram Robert Alexander |
Director |
• • – |
2022-02-28 |
4 |
A |
$16.61 |
$18,736 |
D/D |
1,128 |
80,060 |
|
- |
|
| Levin Alan G |
Director |
• • – |
2022-02-28 |
4 |
A |
$16.61 |
$9,999 |
D/D |
602 |
2,059 |
|
- |
|
| Abercrombie George B |
Director |
• • – |
2022-02-15 |
4 |
AS |
$18.50 |
$92,500 |
D/D |
(5,000) |
0 |
|
-42% |
|
| Abercrombie George B |
Director |
• • – |
2022-02-15 |
4 |
OE |
$3.32 |
$16,600 |
D/D |
5,000 |
5,000 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2022-01-11 |
4 |
AS |
$15.04 |
$2,767,360 |
D/D |
(184,000) |
901,602 |
|
-45% |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2022-01-11 |
4 |
OE |
$4.73 |
$870,320 |
D/D |
184,000 |
1,085,602 |
|
- |
|
| Barnes Alane P |
Chief Legal Officer |
• • – |
2021-12-14 |
4/A |
A |
$0.00 |
$0 |
D/D |
55,000 |
201,969 |
|
- |
|
| Gayer Charles K |
Chief Commercial Officer |
• • – |
2021-12-14 |
4/A |
A |
$0.00 |
$0 |
D/D |
80,000 |
216,556 |
|
- |
|
| Doyle Anthony |
Chief Financial Officer |
• • – |
2021-12-14 |
4/A |
A |
$0.00 |
$0 |
D/D |
75,000 |
168,719 |
|
- |
|
| Thackray Helen M. |
Chief R&D Officer |
• • – |
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
44,000 |
144,000 |
|
- |
|
| Jones Michael L |
Exec. Director, Finance - PAO |
• • – |
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
5,850 |
11,198 |
|
- |
|
| Barnes Alane P |
Chief Legal Officer |
• • – |
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
221,969 |
|
- |
|
| Sheridan William P |
Chief Medical Officer |
• • – |
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
50,791 |
|
- |
|
| Doyle Anthony |
Chief Financial Officer |
• • – |
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
115,000 |
208,719 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
123,000 |
901,602 |
|
- |
|
| Babu Yarlagadda S |
Chief Discovery Officer |
• • – |
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
250,056 |
|
- |
|
| Gayer Charles K |
Chief Commercial Officer |
• • – |
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
261,556 |
|
- |
|
| Babu Yarlagadda S |
Chief Discovery Officer |
• • – |
2021-12-07 |
4 |
S |
$12.20 |
$367,220 |
D/D |
(30,100) |
215,056 |
|
16% |
|
| Babu Yarlagadda S |
Chief Discovery Officer |
• • – |
2021-12-07 |
4 |
OE |
$4.73 |
$293,260 |
D/D |
62,000 |
245,156 |
|
- |
|
| Levin Alan G |
Director |
• • – |
2021-11-30 |
4 |
A |
$12.06 |
$9,998 |
D/D |
829 |
1,457 |
|
- |
|
743 Records found
|
|
Page 5 of 30 |
|
|
0.33 (5.11%) 
